In brief
Three years ago, 23andMe was soaring high in the tech industry with a skyrocketing share price and millions of eager customers sending in saliva samples. Today, however, the company is at a crossroads, narrowly evading delisting from the stock market as it grapples with survival issues. Its stock, which reached a high of $321, has since plummeted to nearly $5, representing a staggering decline in value. This downturn raises critical concerns about the security and handling of its extensive database, which includes sensitive information about customers' DNA.
Despite its current struggles, 23andMe remains optimistic about its future. CEO Anne Wojcicki has emphasized the company's commitment to protecting customer data, addressing worries about the implications of its database during difficult times. However, industry experts indicate a lack of sustainable business models and delayed profit avenues—particularly in their plans to leverage genetic data for drug research—have contributed to its demise.Leadership concerns add to the uncertainty surrounding the company, with the board resigning and leaving only Wojcicki from the original team. Rumors of a potential sale have circulated, although the company insists it intends to remain independent. The issue of consumer data privacy looms large, as experts highlight that personal DNA information can have substantial repercussions, not just for individuals but for their families as well, given the genetic data ties involved.Professionals are urging for stronger protections for sensitive personal information, particularly in industries that trade in such data. The stakes are inherently high in the context of DNA data; unlike financial information, genetic data cannot be easily changed or reissued in case of a breach. The situation at 23andMe is a cautionary tale of both the precariousness of tech firms and the vital need for robust privacy protections in an age of data monetization.
